世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Nicotinamide Mononucleotide (NMN) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of age-dependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately. NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), which plays a vital role in cell metabolism and energy production. As we age, the level of NAD+ in the human body gradually decreases, resulting in weakened cell metabolism, which in turn triggers a series of aging-related diseases. Therefore, increasing the level of NAD+ in the body by supplementing NMN has become a new way to fight aging and maintain good health. With the general improvement of global health awareness and continuous breakthroughs in scientific research and technology, the growth momentum of the NMN market will continue to increase. In the future, the NMN market will achieve a deeper cross-border integration with other health industries such as biotechnology, precision medicine, and nutritional supplements, giving rise to a series of innovative products and service models to meet consumers' more personalized and precise health needs. At present, nicotinamide mononucleotide (NMN) is still in the development stage. There are not many manufacturers in the global market, and consumers have weak awareness of its use, especially in developing countries. The demand is lower than that in developed countries around the world, but the demand in developing countries is growing rapidly. Leading giants have proposed expansion plans and increased production bases. Nicotinamide mononucleotide (NMN) core manufacturers include GeneHarbor, Mirailab Bioscience, Maac10 Formulas, Herbalmax and Genex Formula. China is the largest production area, accounting for about 84% of the global market share, followed by North America and Japan. The downstream applications of nicotinamide mononucleotide include health products, cosmetics, etc. Globally, health products are the largest application market, and raw materials for health products account for 99% of the total sales of nicotinamide mononucleotide in 2023. This report aims to provide a comprehensive presentation of the global market for Nicotinamide Mononucleotide (NMN), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Nicotinamide Mononucleotide (NMN) by region & country, by Type, and by Application. The Nicotinamide Mononucleotide (NMN) market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nicotinamide Mononucleotide (NMN). Market Segmentation By Company GeneHarbor Herbalmax Genex Formulas Mirailab Bioscience Maac10 Formulas EffePharm Bontac CELFULL Kingdomway ABA Chemical Segment by Type Content ≥98% Content ＜98% Segment by Application Health Care Products Cosmetics Others By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Europe Germany France U.K. Italy Netherlands Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Nicotinamide Mononucleotide (NMN) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Sales, revenue of Nicotinamide Mononucleotide (NMN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Sales, revenue of Nicotinamide Mononucleotide (NMN) in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Table of Contents1 Market Overview1.1 Nicotinamide Mononucleotide (NMN) Product Introduction 1.2 Global Nicotinamide Mononucleotide (NMN) Market Size Forecast 1.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Value (2020-2031) 1.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume (2020-2031) 1.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Price (2020-2031) 1.3 Nicotinamide Mononucleotide (NMN) Market Trends & Drivers 1.3.1 Nicotinamide Mononucleotide (NMN) Industry Trends 1.3.2 Nicotinamide Mononucleotide (NMN) Market Drivers & Opportunity 1.3.3 Nicotinamide Mononucleotide (NMN) Market Challenges 1.3.4 Nicotinamide Mononucleotide (NMN) Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Nicotinamide Mononucleotide (NMN) Players Revenue Ranking (2024) 2.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Company (2020-2025) 2.3 Global Nicotinamide Mononucleotide (NMN) Players Sales Volume Ranking (2024) 2.4 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Company Players (2020-2025) 2.5 Global Nicotinamide Mononucleotide (NMN) Average Price by Company (2020-2025) 2.6 Key Manufacturers Nicotinamide Mononucleotide (NMN) Manufacturing Base and Headquarters 2.7 Key Manufacturers Nicotinamide Mononucleotide (NMN) Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Nicotinamide Mononucleotide (NMN) 2.9 Nicotinamide Mononucleotide (NMN) Market Competitive Analysis 2.9.1 Nicotinamide Mononucleotide (NMN) Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Nicotinamide Mononucleotide (NMN) Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nicotinamide Mononucleotide (NMN) as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Content ≥98% 3.1.2 Content ＜98% 3.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Type 3.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Value, by Type (2020-2031) 3.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Value, by Type (%) (2020-2031) 3.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type 3.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume, by Type (2020-2031) 3.3.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume, by Type (%) (2020-2031) 3.4 Global Nicotinamide Mononucleotide (NMN) Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Health Care Products 4.1.2 Cosmetics 4.1.3 Others 4.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Application 4.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Value, by Application (2020-2031) 4.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Value, by Application (%) (2020-2031) 4.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Application 4.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume, by Application (2020-2031) 4.3.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume, by Application (%) (2020-2031) 4.4 Global Nicotinamide Mononucleotide (NMN) Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region 5.1.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region (2020-2025) 5.1.3 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region (2026-2031) 5.1.4 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region (%), (2020-2031) 5.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Region 5.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Region (2020-2025) 5.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Region (2026-2031) 5.2.4 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Region (%), (2020-2031) 5.3 Global Nicotinamide Mononucleotide (NMN) Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 5.4.2 North America Nicotinamide Mononucleotide (NMN) Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 5.5.2 Europe Nicotinamide Mononucleotide (NMN) Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 5.6.2 Asia Pacific Nicotinamide Mononucleotide (NMN) Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 5.7.2 South America Nicotinamide Mononucleotide (NMN) Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 5.8.2 Middle East & Africa Nicotinamide Mononucleotide (NMN) Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Nicotinamide Mononucleotide (NMN) Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Nicotinamide Mononucleotide (NMN) Sales Value and Sales Volume 6.2.1 Key Countries/Regions Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.2.2 Key Countries/Regions Nicotinamide Mononucleotide (NMN) Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.3.2 United States Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.4.2 Europe Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.5.2 China Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.5.3 China Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.6.2 Japan Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.7.2 South Korea Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.8.2 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Nicotinamide Mononucleotide (NMN) Sales Value, 2020-2031 6.9.2 India Nicotinamide Mononucleotide (NMN) Sales Value by Type (%), 2024 VS 2031 6.9.3 India Nicotinamide Mononucleotide (NMN) Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 GeneHarbor 7.1.1 GeneHarbor Company Information 7.1.2 GeneHarbor Introduction and Business Overview 7.1.3 GeneHarbor Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 GeneHarbor Nicotinamide Mononucleotide (NMN) Product Offerings 7.1.5 GeneHarbor Recent Development 7.2 Herbalmax 7.2.1 Herbalmax Company Information 7.2.2 Herbalmax Introduction and Business Overview 7.2.3 Herbalmax Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Herbalmax Nicotinamide Mononucleotide (NMN) Product Offerings 7.2.5 Herbalmax Recent Development 7.3 Genex Formulas 7.3.1 Genex Formulas Company Information 7.3.2 Genex Formulas Introduction and Business Overview 7.3.3 Genex Formulas Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Genex Formulas Nicotinamide Mononucleotide (NMN) Product Offerings 7.3.5 Genex Formulas Recent Development 7.4 Mirailab Bioscience 7.4.1 Mirailab Bioscience Company Information 7.4.2 Mirailab Bioscience Introduction and Business Overview 7.4.3 Mirailab Bioscience Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Mirailab Bioscience Nicotinamide Mononucleotide (NMN) Product Offerings 7.4.5 Mirailab Bioscience Recent Development 7.5 Maac10 Formulas 7.5.1 Maac10 Formulas Company Information 7.5.2 Maac10 Formulas Introduction and Business Overview 7.5.3 Maac10 Formulas Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Maac10 Formulas Nicotinamide Mononucleotide (NMN) Product Offerings 7.5.5 Maac10 Formulas Recent Development 7.6 EffePharm 7.6.1 EffePharm Company Information 7.6.2 EffePharm Introduction and Business Overview 7.6.3 EffePharm Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 EffePharm Nicotinamide Mononucleotide (NMN) Product Offerings 7.6.5 EffePharm Recent Development 7.7 Bontac 7.7.1 Bontac Company Information 7.7.2 Bontac Introduction and Business Overview 7.7.3 Bontac Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Bontac Nicotinamide Mononucleotide (NMN) Product Offerings 7.7.5 Bontac Recent Development 7.8 CELFULL 7.8.1 CELFULL Company Information 7.8.2 CELFULL Introduction and Business Overview 7.8.3 CELFULL Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 CELFULL Nicotinamide Mononucleotide (NMN) Product Offerings 7.8.5 CELFULL Recent Development 7.9 Kingdomway 7.9.1 Kingdomway Company Information 7.9.2 Kingdomway Introduction and Business Overview 7.9.3 Kingdomway Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Kingdomway Nicotinamide Mononucleotide (NMN) Product Offerings 7.9.5 Kingdomway Recent Development 7.10 ABA Chemical 7.10.1 ABA Chemical Company Information 7.10.2 ABA Chemical Introduction and Business Overview 7.10.3 ABA Chemical Nicotinamide Mononucleotide (NMN) Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 ABA Chemical Nicotinamide Mononucleotide (NMN) Product Offerings 7.10.5 ABA Chemical Recent Development 8 Industry Chain Analysis 8.1 Nicotinamide Mononucleotide (NMN) Industrial Chain 8.2 Nicotinamide Mononucleotide (NMN) Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Nicotinamide Mononucleotide (NMN) Sales Model 8.5.2 Sales Channel 8.5.3 Nicotinamide Mononucleotide (NMN) Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（ケミカル）の最新刊レポート
QYResearch社の 化学・材料分野 での最新刊レポート
本レポートと同じKEY WORD（demand）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
